ARPO:NSD-Aerpio Pharmaceuticals Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 26.00

Change

0.00 (0.00)%

Market Cap

USD 0.10B

Volume

0.17M

Avg Analyst Target

USD 22.00 (-15.38%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Aerpio Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing compounds that activate Tie2 for the treatment of ocular disease and vascular stabilization. The company's lead product candidate is razuprotafib, a small molecule inhibitor of vascular endothelial protein tyrosine phosphatase , which has completed phase IIb clinical trial for the treatment of non-proliferative diabetic retinopathy, as well as has completed phase II clinical trial for the treatment of patients with open angle glaucoma/ocular hypertension. It also develops ARP-1536, a humanized monoclonal antibody that is in preclinical development stage for the treatment of diabetic vascular complications, including nephropathy and diabetic macular edema; and bispecific antibody for the treatment for wet age-related macular degeneration and DME through intravitreal injection. Aerpio Pharmaceuticals, Inc. has a licensing and collaboration agreement with Gossamer Bio, Inc. for the development and commercialization of GB004, a selective stabilizer of hypoxia-inducible factor-1 alpha, which has completed Phase 1b clinical trial for the treatment of inflammatory bowel disease. The company is headquartered in Cincinnati, Ohio.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-10-18 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MRNA Moderna Inc

+10.63 (+3.28%)

USD130.87B 38.30 29.43
BNTX BioNTech SE

+13.41 (+5.41%)

USD60.07B 13.82 10.18
REGN Regeneron Pharmaceuticals Inc

-9.76 (-1.76%)

USD59.17B 9.99 7.57
VRTX Vertex Pharmaceuticals Incorpo..

-0.97 (-0.53%)

USD47.16B 23.96 15.75
ALXN Alexion Pharmaceuticals Inc

N/A

USD40.34B 59.23 42.56
BGNE BeiGene Ltd

+2.38 (+0.66%)

USD33.45B N/A N/A
SGEN Seagen Inc

-0.76 (-0.44%)

USD31.43B 53.89 40.74
GMAB Genmab A/S

+0.07 (+0.16%)

USD29.05B 74.96 8.12
ALNY Alnylam Pharmaceuticals Inc

-4.66 (-2.23%)

USD24.79B N/A N/A
RPRX Royalty Pharma plc

-1.37 (-3.57%)

USD23.31B 31.09 11.82

ETFs Containing ARPO

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 76.87% N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 76.87% N/A N/A N/A N/A
Trailing 12 Months  
Capital Gain 27.45% N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 27.45% N/A N/A N/A N/A
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 5.66% N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 5.66% N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 81.30% N/A N/A N/A N/A
Risk Adjusted Return 6.96% N/A N/A N/A N/A
Market Capitalization 0.10B N/A N/A N/A N/A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 2.98 N/A N/A N/A N/A
Price / Cash Flow Ratio -19.47 N/A N/A N/A N/A
EV/EBITDA 0.24 N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -47.61% N/A N/A N/A N/A
Return on Invested Capital -15.77% N/A N/A N/A N/A
Return on Assets -31.02% N/A N/A N/A N/A
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 1.81 N/A N/A N/A N/A
Short Percent 10.63% N/A N/A N/A N/A
Beta 1.65 N/A N/A N/A N/A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Negative cashflow

The company had negative total cash flow in the most recent four quarters.